Compare Organon & Co. Common Stock (OGN) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Payoneer Global Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Payoneer Global Inc trades at $7.12 (market cap $2.42B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Payoneer Global Inc for 62 Days on average.
| OGN | PAYO | |
|---|---|---|
Market Cap | $3.62B | $2.42B |
Volume | 2,892,999 | 1,032,721 |
Sector | Health | Technology |
52-Week High | $13.81 | $7.18 |
52-Week Low | $5.70 | $4.27 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $11.04B | $2.16B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Payoneer Global (PAYO) trades at $7.14, up 0.28% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. Fundamentally, the company reported Q2 2026 earnings of $0.02 per share, missing estimates, but revenue grew 10% excluding interest. Recent news highlights the renewal of its partnership with Etsy through 2029 and an agreement to be acquired by Nuvei, announced on June 15, 2026.
The outlook is shaped by the pending acquisition, which offers a potential exit for shareholders, but execution risks and recent earnings misses pose concerns. Analyst sentiment is positive with a 60% buy rating, yet investors should weigh acquisition certainty against operational performance volatility and competitive pressures in the fintech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
